Data from the Phase 3 PALOMA-3 study showed non-inferiority to intravenous administration meeting both co-primary pharmacokinetic (PK) endpoints, as well as a five-fold reduction in infusion-related ...
DelveInsight’s c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline ...
During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and toxicity management in patients with EGFR-mutated non–small cell lung ...
It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because ... future events or circumstances or otherwise. [1] EGFR = epidermal growth factor receptor; TKI ...
It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because ... future events or circumstances or otherwise. 1 EGFR = epidermal growth factor receptor; TKI ...
It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or ...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New ...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug ...
Hope is not passive wishing but an active, dynamic process. According to Hope Theory, hope involves two components: agency and pathways. Agency is the belief in one’s capability to act ...
It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such ... future events or circumstances or otherwise. 1 EGFR = epidermal growth factor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback